Anti-CD40 therapeutic antibody (Pre-made Lucatumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lucatumumab (CHIR 12.12 or HCD122) is a human monoclonal antibody against CD40 development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-325-1mg	1mg	3090
GMP-Bios-ab-325-10mg	10mg	21890
GMP-Bios-ab-325-100mg	100mg	148000
GMP-Bios-ab-325-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-CD40 therapeutic antibody (Pre-made Lucatumumab biosimilar,Whole mAb)
INN Name	Lucatumumab
Target	CD40
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2007
Year Recommended	2008
Companies	Novartis;XOMA
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Chronic lymphocytic leukaemia;Follicular lymphoma;Lymphoma;Multiple myeloma
Development Tech	na